5 billion people have access to medicine 2 billion to go


The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Who we are
What we analyse
How we drive change

New online: the case for fixing the global antibiotic market

White Paper on Antibiotic Shortages, Stockouts and Scarcity

This new white paper unpacks why antibiotic supply chains are failing and how this will have a global impact on basic healthcare. It makes the case for fixing the antibiotic market through coordinated action by governments, regulators and industry.

Index added to new online toolbox for impact investors

13 Jul 2018
The Access to Medicine Index and AMR Benchmark have been added to Navigating Impact, a new online resource center developed specifically for impact investors. This is the latest example of the Foundation’s research and metrics being integrated into investor platforms, following the Bloomberg Terminal and the Sustainability Accounting Standards Board.

Experts gather to discuss proposals for 2020 Antimicrobial Resistance Benchmark

27 Jun 2018
The Expert Committee for the AMR Benchmark meets in Amsterdam on July 2. The agenda is topped by targeted proposals for refining the Benchmark methodology for 2020.

Access to Medicine Index gains first Japanese signatory investor

08 Jun 2018
Sumitomo Mitsui Trust Holdings is the latest investor to publicly endorse the Access to Medicine Index, becoming the 68th signatory to the Index investor statement. The Tokyo-based company manages assets of USD 497 billion.

Access to Medicine Foundation makes case for fixing the antibiotic market

31 May 2018
Today, the Access to Medicine Foundation warns that antibiotic supply chains are on the brink of collapse, putting basic healthcare at risk, in a new white paper titled “Shortages, stockouts and scarcity: the issues facing the security of antibiotic supply and the role for pharmaceutical companies”. Urgent action is needed to rebuild the antibiotics market. The paper shows how some pharmaceutical companies are responding.

Work starts on metrics for the 2020 AMR Benchmark

19 Apr 2018
The Access to Medicine Foundation has started the methodology review for the next Antimicrobial Resistance Benchmark. The Foundation is consulting a wide range of experts and stakeholders to explore how to refine its analysis of pharmaceutical company responses to antimicrobial resistance.

Access to Medicine Foundation in India to discuss AMR strategies

12 Mar 2018
India is home to more than a billion people, who face increasing rates of drug resistance. From 12-16 March, the Access to Medicine Foundation will be in New Delhi and Mumbai, India, to meet with Indian-based pharmaceutical companies and government representatives to share ideas and opportunities to limit drug resistance. The Foundation’s Executive Director, Jayasree K. Iyer, will also speak at the Delhi End TB Summit.

The first Benchmark launches at the WEF in Davos

24 Jan 2018
At 14:00 CET on Tuesday 23 January, Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, will launch the first Antimicrobial Resistance Benchmark in a livestreamed WEF press conference.

Live WEF discussion with Bill Gates & Jayasree Iyer at 1pm CET: “New Era For Global Health”

25 Jan 2018
Jayasree K. Iyer joins Bill Gates and others to discuss how new leadership, policy and business models are rewriting the global health playbook.
Access to Medicine Index Cover

Access to Medicine Index 2016

The only in-depth comparison of the world’s largest pharma companies on how they improve access to medicine for the poor.

Visit website

Access to Vaccines Index Cover

Access to Vaccines Index 2017

The first tool to show how vaccine companies are responding to calls to increase access to vaccines.

Visit website

Antimicrobial Resistance Benchmark 2018

The first detailed analysis of pharmaceutical company action against antimicrobial resistance.

Visit website

We’re hiring!

Interested in working toward the next AMR Benchmark ?
The Foundation is looking for an experienced Research Programme Manager to manage the team developing the AMR Benchmark.


Access to medicine: a material issue for investors
Investors engage with the Foundation for insight into our analysis of the pharma sector, including into governance structures, R&D and pricing strategies.

The foundation on Twitter

Access to Medicine's Twitter avatar
Access to Medicine

.@theGIIN's #NavigatingImpact now also points investors toward the #AtMIndex, #AMRBenchmark & #AtVIndex that captu… t.co/sgZRnXwuCy

CIDRAP-ASP's Twitter avatar

With comments on the implications of Novartis' decision and options for a way forward from @AtMIndex executive dire… t.co/9O2qOd24cx

Retweeted by Access to Medicine
Access to Medicine's Twitter avatar
Access to Medicine

The #AtMIndex and #AMRBenchmark have been added to Navigating Impact, a new online resource center developed specif… t.co/Qt5pNvPfPv

Access to Medicine's Twitter avatar
Access to Medicine

The fight against life-threatening infections suffers another blow as big pharma waves white flag t.co/fGniRoYllZ via @business

Access to Medicine's Twitter avatar
Access to Medicine

68 investors have now signed the Access to Medicine Index investor statement. This group collectively manages asset… t.co/5vUezS2F62

Encourage pharma companies Access to Medicine


Incentivising pharma to develop medicine for the poor
Which mechanisms work for engaging pharma companies in R&D for diseases of poverty?

“To improve access, we believe pharmaceutical companies need to focus on how
they deploy their products, and, as global citizens, collaborate on the development of strong health systems.”

Jayasree K. Iyer, Executive Director, Access to Medicine Foundation.


Embedding pro-access governance


Mainstreaming inclusive business models


Improving industry responsiveness to public health priorities


Employing ‘access-thinking’ in product deployment


Addressing unmet needs through R&D

The Access to Medicine Foundation and its publications are funded by